Daewoong wins Indonesian approval for diabetes drug Envlo

Daewoong Pharmaceutical said Wednesday it has won regulatory approval in Indonesia for its type 2 diabetes treatment Envlo (enavogliflozin), marking its entry into Southeast Asia’s largest pharmaceutical market. The drug was approved by Indonesia’s National Agency of Drug and Food Control, Daewoong said. Indonesia has an estimated 20.4 million adults living with diabetes as of 2024, ranking fifth globally, according to the International Diabetes Federation. The country’s diabetes treatment marke